Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

2(22.2%)

Phase 3

2(22.2%)

9Total

Phase 1(5)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07307794Phase 1Recruiting

To Evaluate the Adhesion of TK-254RX on Healthy Participants

Role: lead

NCT06866613Phase 3Completed

Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.

Role: lead

NCT06871046Phase 3Completed

Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions

Role: lead

NCT06870422Phase 1Completed

To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers.

Role: lead

NCT06823284Phase 1Completed

To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects

Role: lead

NCT06042192Phase 1Completed

Open Label Trial to Evaluate the Adhesion of TK-254RX in Healthy Volunteers.

Role: lead

NCT04908748Phase 2Completed

Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain

Role: lead

NCT02729207Phase 2Terminated

Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain

Role: lead

NCT04505787Phase 1Completed

S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet

Role: collaborator

All 9 trials loaded